100 related articles for article (PubMed ID: 16838111)
1. COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic for molecular markers.
Langsenlehner U; Gerger A; Weitzer W; Krippl P
Breast Cancer Res Treat; 2007 Jan; 101(2):247. PubMed ID: 16838111
[No Abstract] [Full Text] [Related]
2. COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic molecular markers.
Millanta F; Citi S; Della Santa D; Porciani M; Poli A
Breast Cancer Res Treat; 2006 Jul; 98(1):115-20. PubMed ID: 16538539
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of feline COX-2 and expression in feline mammary carcinomas.
Sayasith K; Sirois J; Doré M
Vet Pathol; 2009 May; 46(3):423-9. PubMed ID: 19176489
[TBL] [Abstract][Full Text] [Related]
4. Reduced PTEN protein expression and its prognostic implications in canine and feline mammary tumors.
Ressel L; Millanta F; Caleri E; Innocenti VM; Poli A
Vet Pathol; 2009 Sep; 46(5):860-8. PubMed ID: 19429983
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance of immunoexpression of claudin-1 and claudin-7 in feline mammary carcinomas.
Flores AR; Rêma A; Carvalho F; Lopes G; Faustino A; Dias Pereira P
J Comp Pathol; 2014 Nov; 151(4):339-46. PubMed ID: 25246182
[TBL] [Abstract][Full Text] [Related]
6. Cox-2 levels in canine mammary tumors, including inflammatory mammary carcinoma: clinicopathological features and prognostic significance.
Queiroga FL; Perez-Alenza MD; Silvan G; Peña L; Lopes C; Illera JC
Anticancer Res; 2005; 25(6B):4269-75. PubMed ID: 16309227
[TBL] [Abstract][Full Text] [Related]
7. Prognostic histopathological and molecular markers in feline mammary neoplasia.
Hughes K; Dobson JM
Vet J; 2012 Oct; 194(1):19-26. PubMed ID: 22841451
[TBL] [Abstract][Full Text] [Related]
8. Complex carcinomas of the mammary gland in cats: pathological and immunohistochemical features.
Seixas F; Pires MA; Lopes CA
Vet J; 2008 May; 176(2):210-5. PubMed ID: 17459738
[TBL] [Abstract][Full Text] [Related]
9. The expression of p63 and cytokeratin 5 in mixed tumors of the canine mammary gland provides new insights into the histogenesis of these neoplasms.
Ramalho LN; Ribeiro-Silva A; Cassali GD; Zucoloto S
Vet Pathol; 2006 Jul; 43(4):424-9. PubMed ID: 16846983
[TBL] [Abstract][Full Text] [Related]
10. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.
Morris JS; Nixon C; King OJ; Morgan IM; Philbey AW
Vet J; 2009 Mar; 179(3):422-9. PubMed ID: 18314357
[TBL] [Abstract][Full Text] [Related]
11. Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts.
Robertson FM; Mallery SR; Bergdall-Costell VK; Cheng M; Pei P; Prosperi JR; Ferrari M
Anticancer Res; 2007; 27(2):719-27. PubMed ID: 17465194
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome.
Zerkowski MP; Camp RL; Burtness BA; Rimm DL; Chung GG
Cancer Invest; 2007 Feb; 25(1):19-26. PubMed ID: 17364553
[TBL] [Abstract][Full Text] [Related]
13. The potential role of COX-2 in cancer stem cell-mediated canine mammary tumor initiation: an immunohistochemical study.
Huang J; Zhang D; Xie F; Lin D
J Vet Sci; 2015; 16(2):225-31. PubMed ID: 26124697
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 expression in normal and neoplastic canine mammary cell lines.
Brunelle M; Sartin EA; Wolfe LG; Sirois J; Doré M
Vet Pathol; 2006 Sep; 43(5):656-66. PubMed ID: 16966442
[TBL] [Abstract][Full Text] [Related]
15. COX-2 expression in canine normal and neoplastic mammary gland.
Dias Pereira P; Lopes CC; Matos AJ; Santos M; Gärtner F; Medeiros R; Lopes C
J Comp Pathol; 2009 May; 140(4):247-53. PubMed ID: 19203768
[TBL] [Abstract][Full Text] [Related]
16. cDNA microarray profiles of canine mammary tumour cell lines reveal deregulated pathways pertaining to their phenotype.
Rao NA; van Wolferen ME; van den Ham R; van Leenen D; Groot Koerkamp MJ; Holstege FC; Mol JA
Anim Genet; 2008 Aug; 39(4):333-45. PubMed ID: 18462483
[TBL] [Abstract][Full Text] [Related]
17. Expression of cyclooxygenase-2 in canine nasal carcinomas.
Impellizeri JA; Esplin DG
Vet J; 2008 Jun; 176(3):408-10. PubMed ID: 17517527
[TBL] [Abstract][Full Text] [Related]
18. Positive Interplay Between CD3+ T-lymphocytes and Concurrent COX-2/EGFR Expression in Canine Malignant Mammary Tumors.
Carvalho MI; Pires I; Prada J; Ferreira AF; Queiroga FL
Anticancer Res; 2015 May; 35(5):2915-20. PubMed ID: 25964576
[TBL] [Abstract][Full Text] [Related]
19. The search for suitable prognostic markers for canine mammary tumors: A promising outlook.
Zaidan Dagli ML
Vet J; 2008 Jul; 177(1):3-5. PubMed ID: 18054505
[No Abstract] [Full Text] [Related]
20. Gene expression profiles of progestin-induced canine mammary hyperplasia and spontaneous mammary tumors.
Rao NA; van Wolferen ME; Gracanin A; Bhatti SF; Krol M; Holstege FC; Mol JA
J Physiol Pharmacol; 2009 May; 60 Suppl 1():73-84. PubMed ID: 19609016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
